

# Yasser M Fouad

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1432034/yasser-m-fouad-publications-by-year.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

49  
papers

1,651  
citations

18  
h-index

40  
g-index

55  
ext. papers

2,804  
ext. citations

5.4  
avg, IF

4.96  
L-index

#	Paper	IF	Citations
49	MAFLD Not NAFLD is Associated with Impairment of Health-related Quality of Life.. <i>Journal of Clinical and Translational Hepatology</i> , <b>2022</b> , 10, 4-5	5.2	2
48	Redefinition of Fatty Liver Disease from NAFLD to MAFLD through the Lens of Drug Development and Regulatory Science.. <i>Journal of Clinical and Translational Hepatology</i> , <b>2022</b> , 10, 374-382	5.2	1
47	Healthcare ProvidersTPerspective about the Use of Telemedicine in Egypt: A National Survey.. <i>International Journal of Telemedicine and Applications</i> , <b>2022</b> , 2022, 3811068	2.6	
46	Global multi-stakeholder endorsement of the MAFLD definition.. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2022</b> ,	18.8	18
45	Letter to the Editor: Apples should be compared with apples.. <i>Hepatology</i> , <b>2022</b> ,	11.2	1
44	The change from NAFLD to MAFLD expands fatty liver information flow.. <i>Hepatology Research</i> , <b>2022</b> , 52, 488-489	5.1	1
43	Arabic Association for the Study of Diabetes and Metabolism (AASD) endorsing the MAFLD definition of fatty liver disease. <i>Journal of Hepatology</i> , <b>2021</b> ,	13.4	2
42	One not like the other: The weakness of the blood sugar-MAFLD analogy. <i>Journal of Hepatology</i> , <b>2021</b> ,	13.4	1
41	Predictors for Severity of SARS-CoV-2 Infection Among Healthcare Workers. <i>Journal of Multidisciplinary Healthcare</i> , <b>2021</b> , 14, 2973-2981	2.8	3
40	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2021</b> ,	24.2	37
39	Management of liver disease patients in different clinical situations during COVID-19 pandemic. <i>Egyptian Liver Journal</i> , <b>2021</b> , 11, 21	1.6	2
38	Quality of Life after Transcatheter Arterial Chemoembolization Combined with Radiofrequency Ablation in Patients with Unresectable Hepatocellular Carcinoma Compared with Transcatheter Arterial Chemoembolization alone. <i>Asian Pacific Journal of Cancer Prevention</i> , <b>2021</b> , 22, 1255-1261	1.7	0
37	The sub-Saharan Africa position statement on the redefinition of fatty liver disease: From NAFLD to MAFLD. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 1256-1258	13.4	21
36	Capturing patient experience: A qualitative study of change from NAFLD to MAFLD real-time feedback. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 1261-1262	13.4	11
35	Change from NAFLD to MAFLD increases the awareness of fatty liver disease in primary care physicians and specialists. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 1254-1256	13.4	23
34	Nomenclature and definition of metabolic-associated fatty liver disease: a consensus from the Middle East and north Africa. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2021</b> , 6, 57-64	18.8	58
33	The NAFLD-MAFLD debate: Eminence vs evidence. <i>Liver International</i> , <b>2021</b> , 41, 255-260	7.9	31

32	Treatment of Chronic Hepatitis C in Adolescent Patients With Positive HBsAg or With Occult Hepatitis B: Is the Risk of Hepatitis B Reactivation Significant?. <i>Pediatric Infectious Disease Journal</i> , <b>2021</b> , 40, 11-15	3.4	1
31	MAFLD considerations as a part of the global hepatitis C elimination effort: an international perspective. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 53, 1080-1089	6.1	3
30	A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 202-209	13.4	764
29	Revised Nomenclature for Fatty Liver Disease: Cutting through the Confusion. <i>Journal of Clinical and Translational Hepatology</i> , <b>2020</b> , 8, 354-355	5.2	1
28	Clinical Significance of Annexin A4 as a Biomarker in the Early Diagnosis of Hepatocellular Carcinoma. <i>Asian Pacific Journal of Cancer Prevention</i> , <b>2020</b> , 21, 2661-2665	1.7	2
27	Detection of hepatitis C virus core antigen as an alternative method for diagnosis of hepatitis C virus infection in blood donors negative for hepatitis C virus antibody. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2020</b> , 32, 1348-1351	2.2	2
26	Effects of sofosbuvir/ledipasvir therapy on chronic hepatitis C virus genotype 4, infected children of 3-6 years of age. <i>Liver International</i> , <b>2020</b> , 40, 319-323	7.9	5
25	Retreatment of chronic hepatitis C virus genotype-4 patients after non-structural protein 5A inhibitors failure: efficacy and safety of different regimens. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2020</b> , 32, 440-446	2.2	1
24	History of Nonalcoholic Fatty Liver Disease. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	30
23	What's in a name? Renaming NAFSLD to MAFLD <i>Liver International</i> , <b>2020</b> , 40, 1254-1261	7.9	112
22	Predictors of mortality in cases of thermal burns admitted to Burn Unit, Ain Shams University Hospitals, Cairo. <i>Journal of Clinical Forensic and Legal Medicine</i> , <b>2019</b> , 67, 19-23	1.7	0
21	Effectiveness of 8-week sofosbuvir/ledipasvir in the adolescent chronic hepatitis C-infected patients. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2019</b> , 31, 1004-1009	2.2	9
20	The effectiveness and safety of ledipasvir plus sofosbuvir in adolescents with chronic hepatitis C virus genotype 4 infection: a real-world experience. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 47, 838-844	6.1	29
19	Sofosbuvir plus daclatasvir with or without ribavirin in 551 patients with hepatitis C-related cirrhosis, genotype 4. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 47, 674-679	6.1	20
18	Efficacy and safety of sofosbuvir plus simeprevir therapy in Egyptian patients with chronic hepatitis C: a real-world experience. <i>Gut</i> , <b>2017</b> , 66, 2008-2012	19.2	26
17	Cochlear implantation under conscious sedation with local anesthesia; Safety, Efficacy, Costs, and Satisfaction. <i>Cochlear Implants International</i> , <b>2017</b> , 18, 297-303	1.7	19
16	Diagnostic Performance of Multidetector Computed Tomography (MDCT) in Diagnosis of Sinus Variations. <i>Polish Journal of Radiology</i> , <b>2017</b> , 82, 713-725	1.6	7
15	Clinical significance and diagnostic value of serum dickkopf-1 in patients with hepatocellular carcinoma. <i>Scandinavian Journal of Gastroenterology</i> , <b>2016</b> , 51, 1133-7	2.4	15

14	Hepato-cardiac disorders. <i>World Journal of Hepatology</i> , <b>2014</b> , 6, 41-54	3.4	82
13	Chronic hepatitis C-associated thrombocytopenia: aetiology and management. <i>Tropical Gastroenterology: Official Journal of the Digestive Diseases Foundation</i> , <b>2013</b> , 34, 58-67		13
12	Incidence and risk factors of retinopathy in Egyptian patients with chronic hepatitis C virus treated with pegylated interferon plus ribavirin. <i>International Journal of Infectious Diseases</i> , <b>2012</b> , 16, e67-71	10.5	8
11	Hematopoietic stem cell mobilization into the peripheral circulation in patients with chronic liver diseases. <i>Journal of Digestive Diseases</i> , <b>2012</b> , 13, 571-8	3.3	8
10	Hepatitis C virus (genotype 4)-associated mixed cryoglobulinemia vasculitis: effects of antiviral treatment. <i>Hepatology International</i> , <b>2012</b> , 6, 606-12	8.8	10
9	Bile aspiration cytology in diagnosis of bile duct carcinoma: factors associated with positive yields. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , <b>2012</b> , 19, 370-8	2.8	6
8	A randomized trial of 24 versus 48 weeks of peginterferon alpha-2a plus ribavirin in Egyptian patients with hepatitis C virus genotype 4 and rapid viral response. <i>Tropical Gastroenterology: Official Journal of the Digestive Diseases Foundation</i> , <b>2012</b> , 33, 112-7		12
7	Cystatin C: a predictor of hepatorenal syndrome in patients with liver cirrhosis. <i>Hepatology International</i> , <b>2011</b> , 5, 927-33	8.8	25
6	Is irritable bowel syndrome associated with chronic hepatitis C?. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2010</b> , 25, 1285-8	4	10
5	Barrett's esophagus: prevalence and risk factors in patients with chronic GERD in Upper Egypt. <i>World Journal of Gastroenterology</i> , <b>2009</b> , 15, 3511-5	5.6	26
4	Renal duplex Doppler ultrasound in patients with HCV related liver cirrhosis. <i>Tropical Gastroenterology: Official Journal of the Digestive Diseases Foundation</i> , <b>2009</b> , 30, 213-8		2
3	Ineffective esophageal motility: the most common motility abnormality in patients with GERD-associated respiratory symptoms. <i>American Journal of Gastroenterology</i> , <b>1999</b> , 94, 1464-7	0.7	146
2	Oesophageal motility defects associated with nocturnal gastro-oesophageal reflux on proton pump inhibitors. <i>Alimentary Pharmacology and Therapeutics</i> , <b>1999</b> , 13, 1467-71	6.1	39
1	Clinical Validity of the diagnostic criteria for metabolic-associated fatty liver disease: a real-world experience		2